Piramal Pharma Limited has acquired a majority stake in Yapan Bio Private Limited, a Hyderabad-based Contract Development and Manufacturing Organization (CDMO), for an aggregate cash consideration of ₹76 crore. The transaction involved the acquisition of 1.46 lakh equity shares with a face value of ₹10 each from existing shareholders.
The acquisition strengthens Piramal Pharma’s presence in the biologics and vaccine CDMO segment and increases its ownership in Yapan Bio to a level that makes the company a subsidiary. Piramal had previously held a strategic minority stake in Yapan Bio.
Quick Summary
Piramal Pharma has acquired a 74% stake in Yapan Bio for ₹76 crore, making Yapan Bio a subsidiary of Piramal Pharma. Yapan Bio is a Hyderabad-based CDMO focused on biologics and vaccines. The deal strengthens Piramal Pharma’s capabilities in large-molecule development and manufacturing.
Piramal Pharma Yapan Bio Acquisition: Key Details
| Particular | Details |
|---|---|
| Acquirer | Piramal Pharma Limited |
| Target Company | Yapan Bio Private Limited |
| Sector | Pharmaceutical / CDMO |
| Stake Acquired | 74% |
| Shares Acquired | 1.46 lakh equity shares |
| Face Value | ₹10 per share |
| Acquisition Consideration | ₹76 crore |
| Location of Yapan Bio | Hyderabad, India |
| Ownership Status After Deal | Yapan Bio becomes a subsidiary |
| Transaction Type | Acquisition from existing shareholders |
The acquisition was completed through the purchase of equity shares from Yapan Bio’s existing shareholders for an aggregate cash consideration of ₹76 crore.
What Is Yapan Bio?
Yapan Bio Private Limited is a Hyderabad-based CDMO with expertise in the development and manufacturing of biologics, vaccines and other large-molecule products.
Piramal Pharma initially invested in Yapan Bio in December 2021, when it acquired a 27.78% equity stake through an investment of ₹101.77 crore. The investment was intended to strengthen Piramal Pharma Solutions’ capabilities in large molecules, including vaccines and gene therapy.
By its FY2026 annual report, Piramal Pharma reported that it held a 33.33% equity stake in Yapan Bio and classified the company as an associate.
Why Is the Yapan Bio Acquisition Important for Piramal Pharma?
The acquisition is strategically important because it expands Piramal Pharma’s capabilities in biologics and large-molecule CDMO services.
Yapan Bio has capabilities covering areas such as:
- Biologics development
- Vaccine development and manufacturing
- Large-molecule therapeutics
- RNA and DNA products
- Gene therapy-related development
- Clinical-trial material manufacturing
Piramal had earlier highlighted Yapan Bio’s ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.
Piramal Pharma’s Growing CDMO Strategy
Piramal Pharma Solutions is a global CDMO business serving pharmaceutical and biotechnology companies.
The company’s strategy has included strengthening capabilities across complex drug development and manufacturing, including large molecules and biologics.
The Yapan Bio investment fits into this broader strategy by giving Piramal Pharma greater ownership and control over a business with specialised biologics and vaccine capabilities.
Yapan Bio’s Role in Biologics and Vaccine Manufacturing
Yapan Bio’s capabilities are particularly relevant to the growing demand for specialised CDMO services.
Its expanded facility in Hyderabad has included:
- Upstream process development suites
- Downstream process development laboratories
- Analytical development capabilities
- Biosafety infrastructure
- GMP manufacturing support
The company’s expansion has been designed to support the development and manufacturing of clinical-trial materials for biotechnology and pharmaceutical customers.
What Does the ₹76 Crore Acquisition Mean?
The ₹76 crore transaction represents the cash consideration paid by Piramal Pharma for the acquisition of 1.46 lakh equity shares from existing shareholders.
Following the transaction, Piramal Pharma holds a 74% stake in Yapan Bio, giving it majority ownership and resulting in Yapan Bio becoming a subsidiary.
Acquisition at a Glance
1.46 lakh shares
⬇️
₹76 crore cash consideration
⬇️
74% ownership
⬇️
Yapan Bio becomes a Piramal Pharma subsidiary
Why Is This Deal Important for India’s CDMO Industry?
India’s CDMO industry has been attracting increasing interest as global pharmaceutical companies diversify their research, development and manufacturing networks.
Indian CDMOs are benefiting from factors including:
- Global supply-chain diversification
- Growing outsourcing by pharmaceutical companies
- India’s scientific talent pool
- Cost advantages
- Increasing demand for complex manufacturing
- Expansion into biologics and advanced therapies
Industry analysis has also highlighted growing opportunities for Indian CRDMOs in areas such as antibody-drug conjugates and biologics, although project timelines and commercialisation cycles can vary.
Piramal Pharma and Yapan Bio: Previous Relationship
This acquisition is not Piramal Pharma’s first investment in Yapan Bio.
In December 2021, Piramal Pharma announced an investment of ₹101.77 crore in Yapan Bio and acquired a minority stake of 27.78%. The investment was aimed at expanding Piramal Pharma Solutions’ capabilities in large molecules, vaccines and gene therapy.
In 2022, Yapan Bio also expanded its process-development capabilities in Genome Valley, Hyderabad, as part of an $8 million expansion plan.
The latest transaction therefore represents a significant increase in Piramal Pharma’s ownership of Yapan Bio.
Key Takeaways for Pharma Students and Aspirants
For pharmacy and pharmaceutical-sector students, this acquisition is an important example of how the Indian pharma industry is expanding beyond traditional formulations and APIs into CDMO, biologics, vaccines and advanced therapies.
Important Points to Remember
- 💊 Piramal Pharma acquired 74% of Yapan Bio.
- 💰 The acquisition consideration was ₹76 crore.
- 🧬 Yapan Bio operates in the CDMO sector.
- 🧪 Its expertise includes biologics and vaccines.
- 🏢 Yapan Bio becomes a subsidiary of Piramal Pharma.
- 📍 Yapan Bio is based in Hyderabad.
- 🔬 The transaction strengthens Piramal Pharma’s large-molecule capabilities.
Frequently Asked Questions
1. What did Piramal Pharma acquire?
Piramal Pharma acquired a 74% stake in Yapan Bio Private Limited, making Yapan Bio its subsidiary.
2. How much did Piramal Pharma pay for Yapan Bio?
Piramal Pharma paid an aggregate cash consideration of ₹76 crore for the acquired shares.
3. How many Yapan Bio shares were acquired?
The transaction involved the acquisition of 1.46 lakh equity shares, each having a face value of ₹10.
4. What does Yapan Bio do?
Yapan Bio is a CDMO involved in areas including biologics, vaccines and large-molecule development and manufacturing.
5. Where is Yapan Bio located?
Yapan Bio is based in Hyderabad, Telangana.
6. What percentage of Yapan Bio does Piramal Pharma now own?
Following the acquisition, Piramal Pharma owns 74% of Yapan Bio.
7. Did Piramal Pharma already have a stake in Yapan Bio?
Yes. Piramal Pharma had previously held a minority stake in Yapan Bio. Its FY2026 annual report reported a 33.33% stake before the latest acquisition.
8. Why is this acquisition significant?
The acquisition strengthens Piramal Pharma’s position in biologics, vaccines and large-molecule CDMO services, areas that are becoming increasingly important in pharmaceutical development and manufacturing.
Conclusion
The Piramal Pharma Yapan Bio acquisition marks a significant expansion of Piramal Pharma’s ownership in the Hyderabad-based CDMO. By acquiring a 74% stake for ₹76 crore, Piramal Pharma has made Yapan Bio a subsidiary and strengthened its position in biologics, vaccines and large-molecule development and manufacturing.
The deal also highlights the growing importance of specialised CDMO capabilities in India’s pharmaceutical industry. For pharmacy students and professionals, it reflects the expanding role of biologics, advanced therapies, contract development and manufacturing in the future of pharma.
Recommended Products
